<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00080132</url>
  </required_header>
  <id_info>
    <org_study_id>MRL 2002-003</org_study_id>
    <nct_id>NCT00080132</nct_id>
  </id_info>
  <brief_title>Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy</brief_title>
  <official_title>An Open-Label, Dose-Escalating Efficacy and Safety Study of Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Research Laboratories International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Research Laboratories International</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if implitapide is effective in lowering&#xD;
      triglyceride (TG) levels in patients with Fredrickson Type I or V hypertriglyceridemia where&#xD;
      the maximum tolerable medication and diet were not sufficient.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>October 2004</start_date>
  <completion_date>April 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>50</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>implitapide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In order to participate in this study, patients must meet all of the following inclusion&#xD;
        criteria:&#xD;
&#xD;
          -  be between 8 and 70 years old with diagnosis of Fredrickson Type I or V HTG&#xD;
&#xD;
          -  be stable on current maximum tolerated triglyceride lowering therapy&#xD;
&#xD;
          -  have a fasting TG level of at least 880 mg/dL (10 mmol/L)&#xD;
&#xD;
          -  be male or nonpregnant, nonbreastfeeding female. The women in the study must be&#xD;
             surgically sterile, postmenopausal or must practice an effective method of birth&#xD;
             control&#xD;
&#xD;
          -  must be able to give informed consent or if under the age of 18, parents or legal&#xD;
             guardians must give their informed consent&#xD;
&#xD;
          -  meet body weight requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent heart attack, coronary artery intervention, coronary bypass surgery, or stroke.&#xD;
&#xD;
          -  Patients with class 3 or 4 heart failure&#xD;
&#xD;
          -  Uncontrolled hypothyroidism or other uncontrolled endocrine disease&#xD;
&#xD;
          -  Known, clinically significant eye abnormalities, such as cataracts&#xD;
&#xD;
          -  History of hepatic disease or AST or ALT levels greater than 1.5 x ULN at Visit 1&#xD;
&#xD;
          -  Alkaline phosphatase greater than 2 times ULN&#xD;
&#xD;
          -  Serum creatinine greater than 2.0 mg/dL&#xD;
&#xD;
          -  Liver cirrhosis and severe liver steatosis&#xD;
&#xD;
          -  Clinically significant infection, malignancy, or psychosis&#xD;
&#xD;
          -  Use of oral anticoagulants or digoxin unless the dose is stable and is regularly&#xD;
             monitored&#xD;
&#xD;
          -  Participation in any other investigational study within the last 30 days&#xD;
&#xD;
          -  Breastfeeding or pregnant&#xD;
&#xD;
          -  Current drug or alcohol abuse&#xD;
&#xD;
          -  Serious or unstable medical conditions that would compromise the patient's safety or&#xD;
             successful participation in the study&#xD;
&#xD;
          -  Unwillingness to comply with study procedures or unwillingness to cooperate fully&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Metabolic and Atherosclerosis Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Noord</name>
      <address>
        <city>Groningen</city>
        <zip>9711 SG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Leiden</name>
      <address>
        <city>Leiden</city>
        <zip>2311 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <zip>3021 HC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Oost</name>
      <address>
        <city>Velp</city>
        <zip>6883 HM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Zoetermeer</name>
      <address>
        <city>Zoetermeer</city>
        <zip>2724 EK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lipidklinikken - Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2005</verification_date>
  <study_first_submitted>March 23, 2004</study_first_submitted>
  <study_first_submitted_qc>March 24, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2004</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>HTG</keyword>
  <keyword>Hypertriglyceridemia, Fredrickson Type I</keyword>
  <keyword>Hypertriglyceridemia, Fredrickson Type V</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

